ABDJKLMNOPQRSTUVWXYZAAABACADAE
1
Systemic therapy classMechanism of actionDrugBrand name
Open clinical trial(s)
Available off label
2
Targeted TherapyEGFR inhibitorAfatinibGilotrifYesYes
3
CetuximabErbituxYesYes
4
GefitinibIressa
Yes (not in the U.S.)
5
ErlotinibTarcevaYesYes
6
LapatinibTykerbYes
7
8
CDK4/6 inhibitorPalbociclibIbranceYesYes
9
Yes
10
11
CDK9 inhibitorKB-0742Yes
12
13
mTOR inhibitorSirolimusRapamuneYes
14
EverolimusAfinitorYes
15
TemsirolimusToricelYesYes
16
17
EZH2 inhibitorTazemetostatTazverikYes
18
19
PDGFR inhibitorImatinibGleevecYes
20
SorafenibNexavarYes
21
SunitinibSutentYesYes
22
23
SINE/XPO1SelinexorXpovioYes
24
25
VEGF inhibitorRegorafenibStivargaYesYes
26
Yes
27
PazopanibVotrientYes
28
BevacizumabAvastinYes
29
30
Immune Checkpoint InhibitorPD-1/PD-L1 inhibitorAtezolizumabTecentriqYes
31
AvelumabBavencioYes
32
DurvalumabImfinziYesYes
33
NivolumabOpdivoYesYes
34
Yes
35
Yes
36
Yes
37
38
PembrolizumabKeytrudaYesYes
39
Yes
40
41
M7824Yes
42
43
Therapeutic VaccineAnti-brachyury vaccineGI-6301 vaccineYes (on hold)
44
45
Autologous tumor vaccine
MVX-ONCO-1Yes
46
47
ChemotherapyINT230-6Yes
48
49
AnifolatePemetrexedAlimtaYesYes
50
51
To be included in this table, the mechanism of action (MOA) must be:
1. An MOA that the Chordoma Foundation Medical Advisory Board has recommended be explored in a clinical trial for chordoma
OR
2. Any MOA that has been studied in a Phase 2 trial for chordoma
AND
3. The drugs/therapies listed for each mechanism are either currently being studied in a clinical trial that is enrolling chordoma patients or are available off-label
52
53
© 2018 Chordoma Foundation
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100